Original Research Article
Clinical Efficacy and Safety of Donepezil on Cognitive and Global Function in Patients with Alzheimer’s Disease
Homma A.a · Takeda M.b · Imai Y.c · Udaka F.d · Hasegawa K.e · Kameyama M.d · Nishimura T.f
A 24-Week, Multicenter, Double-Blind, Placebo-Controlled Study in Japan
aTokyo Metropolitan Institute of Gerontology, Tokyo, bOsaka University Graduate School of Medicine, Osaka, cSt. Marianna University School of Medicine, Toyoko Hospital, Kanagawa, dSumitomo Hospital, Osaka, eSt. Marianna University School of Medicine, Kanagawa, fKoshien University, Hyogo, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
This study evaluated efficacy and safety of donepezil hydrochloride (donepezil) at 5 mg/day in patients with mild to moderately severe Alzheimer’s disease for 24 weeks in a double-blind, placebo-controlled comparative trial. In this study, 268 patients were enrolled and 39 of these (15%) were withdrawn. In the evaluable population of efficacy, Protocol-Compatible (PC) analyzed patients (n = 228), better effects than that of placebo were confirmed using two primary efficacy measures: a cognitive performance test, the Japanese version of the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-J cog, p = 0.003) and a clinical global assessment, the Japanese version of the Clinical Global Impression of Change (J-CGIC, p = 0.000). The superiority of donepezil was also shown by secondary measures: the Sum of the Boxes of the Clinical Dementia Rating (CDR-SB), the Mental Function Impairment Scale (MENFIS) and the caregiver-rated modified Crichton scale (CMCS). The same results were obtained in the intention-to-treat (ITT) analysis (n = 263). The incidence of drug-related adverse events was 10% (14/136) in the donepezil and 8% (10/131) in the placebo group; no significant difference was seen between the two groups. The main adverse events were gastrointestinal symptoms, and these were almost all mild, and they all disappeared with continued administration or temporary discontinuation of donepezil. These results indicate that the donepezil appears to be effective and well tolerated in patients with mild to moderately severe Alzheimer’s disease.
© 2000 S. Karger AG, Basel
- Bowen DM, Smith CB, White P, Davison AN: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976;99:459–496.
Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976;ii:1403.
Perry EK, Perry RH, Blessed G, Tomlinson BE: Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;ii:189.
Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Rerry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;ii:1457–1459.
- Whitehouse PJ, Price DL, Clark AW, Coyle JT, Delong MR: Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122–126.
- Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–417.
Yamanishi Y, Kosasa T, Kuriya Y, Matsui K, Kanai K: Inhibitory effects of donepezil hydrochloride on cholinesterase activities in brain, blood and peripheral tissues of young adult rats in comparison with aged rats. Jpn Pharmacol Ther 1998;26(suppl):1277–1294.
- Rogers SL, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021–1031.
- Rogers SL, Farlow MR, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136–145.
Homma A, Imai Y, Hariguchi S, Hasegawa K, Kameyama M, Nishimura T: Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia: 12-week double-blind, placebo-controlled study, 3 mg/day, 5 mg/day. Clin Evaluation 1998;26:251–284.
Homma A, Fukuzawa K, Tsukada Y, Ishii T, Hasegawa K, Mohs RC: Development of a Japanese version of Alzheimer’s disease Assessment Scale (ADAS). Jpn J Geriatr Psychiatry 1992;3:647–655.
- Berg L: Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;24:637–639.
Homma A, Niina R, Ishii T, Hasegawa K: Development of a new rating scale for dementia in the elderly: Mental Function Impairment Scale (MENFIS). Jpn J Geriatr Psychiatry 1991;2:1217–1222.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994, pp 143–146.
- Anthony JC, LeResche L, Niaz U, Von Korff MR, Folstein MF: Limits of the ‘Mini-Mental State’ as a screening test for dementia and delirium among hospital patients. Psychol Med 1982:12:397–408.
- Mohs RC, Rosen WG, Davis KL: The Alzheimer’s Disease Assessment Scale: An instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19:448–450.
- Zec RF, Landreth ES, Vicari SK, Feldman E, Belman J, Andrise A, Robbs R, Kumar V, Becker R: Alzheimer Disease Assessment Scale: Useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1992;6:89–102.
- Hachinski VC, Hiff LD, Zalkha E: Cerebral blood flow in dementia. Arch Neurol 1975;32:632–637.
World Medical Association: Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects. Med J Aust 1976;i:206–207.
Kato S, Homma A, Utsuki T: Assessment Scale of Cognitive Dysfunction in the Questionnaire Form (4): Alzheimer’s Disease Assessment Scale. Jpn J Geriatr Psychiatry 1996;7:1355–1367.
Guy W (ed): Clinical Global Impressions (CGI); in: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, US Department of Health, Education, and Welfare, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp 218–222.
- Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Moris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS, the Tacrine Collaborative Study Group: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 1992;327:1253–1259.
- Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J: A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992;268:2523–2529.
- Rogers SL, Friedhoff LT, the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293–303.
- Knopman DS, Knapp MJ, Gracon SI, Davis CS: The Clinician Interview-Based Impression (CIBI): A clinician’s global change rating scale in Alzheimer’s disease. Neurology 1994;44:2315–2321.
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH: The Alzheimer’s Disease Cooperative Study: Validity and reliability of the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11(suppl 2):22–32.
- Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
- Burke WJ, Miller JP, Rubin EH, Morris JC, Coben LA, Duchek J, Wittels IG, Berg L: Reliability of the Washington University Clinical Dementia Rating. Arch Neurol 1988;45:31–32.
Homma A, Asada T, Arai H, Isse K, Imai Y, Nishikawa T, Kobune S, Utsuki T, Kimura F: Clinical assessment for patients with age-associated dementia: Global and psychometric assessment. Jpn J Geriatr Psychiatry 1999;10:193–229.
Robinson RA: Some problems of clinical trials in elderly people. Gerontol Clin 1961;3:247–257.
Morrison DP: The Crichton Visual Analogue Scale for the assessment of behavior in the elderly. Acta Psychiatr Scand 1983;68:408–413.
Imai Y, Hasegawa K, Homma A: Recent epidemiological study on senile dementia: Kanagawa prefecture. Geriatr Dement 1994;8:57–64.
Ministry of Health and Welfare Japan, Pharmaceutical and Medical Safety Bureau: Adverse Drug Reaction Terminology. Tokyo, Ministry of Health and Welfare Japan, 1996.
- Stern RG, Mohs RC, Davidson M, Schmeider J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL: A longitudinal study of Alzheimer’s disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390–396.
Yamashita H, Mori E: The change with time of cognitive function in Alzheimer’s disease: Special reference to ADAS. Jpn J Geriatr Psychiatry 1996;7:883–888.
Homma A: The Alzheimer’s Disease Assessment Scale and a possibility of a shortened Japanese version; in Bergener M, Belmarker RH, Tropper MS (eds): Psychopharmacotherapy for the Elderly: Research and Clinical Implications. New York, Springer, 1993.
- Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92:12260–12264.
- Utermann G: Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433–440.
- Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Glanski B: Metrifonate treatment of AD: Influence of APOE genotype. Neurology 1999;53:2010–2016.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.